The Utility of FDG-PET for Radiation Treatment in NSCLC

This study is currently recruiting participants.
Verified August 2011 by Alberta Health Services
Sponsor:
Collaborator:
Calgary Health Region
Information provided by:
Alberta Health Services
ClinicalTrials.gov Identifier:
NCT00385164
First received: October 4, 2006
Last updated: January 18, 2012
Last verified: August 2011

October 4, 2006
January 18, 2012
October 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00385164 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Utility of FDG-PET for Radiation Treatment in NSCLC
The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)

Patients planned for radical radiation for NSCLC will undergo conventional CT stimulation and also PET/CT scans for definition of radiation target volumes

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Non-small cell lung cancer

  • Lung Neoplasms
  • Positron Emission Tomography
Procedure: PET/CT scan for RT planning
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
Not Provided
Not Provided

Inclusion Criteria:

  • Non-small cell lung cancer to receive radical radiation

Exclusion Criteria:

  • unable to tolerate PET/CT scan
Both
18 Years and older
No
Contact: Harold P Lau, MD 403-521-3012
Canada
 
NCT00385164
20328, E-20328
Not Provided
Not Provided
Alberta Health Services
Calgary Health Region
Principal Investigator: Harold P Lau, MD Alberta Health Services
Alberta Health Services
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP